Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT

Srinivasan Beddu, MD; Glenn M. Chertow, MD; Tom Greene, PhD; Paul K. Whelton, MB, MD, MSc; Walter T. Ambrosius, PhD; Alfred K. Cheung, MD; Jeffrey Cutler, MD; Lawrence Fine, MD; Robert Boucher, BS; Guo Wei, MS; Chong Zhang, MS; Holly Kramer, MD, MPH; Adam P. Bress, PharmD, MS; Paul L. Kimmel, MD; Suzanne Oparil, MD; Cora E. Lewis, MD, MSPH; Mahboob Rahman, MD; William C. Cushman, MD

Background—Intensive systolic blood pressure (SBP) lowering significantly reduced cardiovascular disease (CVD) events in SPRINT (Systolic Blood Pressure Intervention Trial) but not in ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure).

Methods and Results—SPRINT tested the effects of intensive (<120 mm Hg) versus standard (<140 mm Hg) SBP goals on CVD events and all-cause mortality. Using a 2×2 factorial design, ACCORD BP tested the same SBP intervention in addition to an intensive versus standard glycemia intervention. We compared the effects of intensive SBP lowering on the composite CVD endpoint similarly in SPRINT (hazard ratio: 0.75; 95% confidence interval, 0.64–0.89) and in the ACCORD BP standard glycemia arm (hazard ratio: 0.77; 95% confidence interval, 0.63–0.95; interaction P=0.87). However, the effect of intensive SBP lowering on the composite CVD endpoint in the ACCORD BP intensive glycemia arm (hazard ratio: 1.04; 95% confidence interval, 0.83–1.29) was significantly different from SPRINT (interaction P=0.023). Patterns were similar for all-cause mortality.

Conclusions—The effects of intensive SBP control on CVD events and all-cause mortality were similar in patients without diabetes mellitus and in those with diabetes mellitus on standard glycemic control. An interaction between intensive SBP lowering and intensive glycemic control may have masked beneficial effects of intensive SBP lowering in ACCORD BP.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifiers: NCT01206062, NCT00000620. (J Am Heart Assoc. 2018;7:e009326. DOI: 10.1161/JAHA.118.009326.)

Key Words: cardiovascular outcomes • diabetes mellitus • high blood pressure • hypertension
Intensive SBP Control and CVD Events  Bedhu et al

Clinical Perspective

What Is New?

- Previous data showed that intensive systolic blood pressure lowering compared with standard systolic blood pressure control (goal <120 versus <140 mm Hg) was beneficial in patients without diabetes mellitus in SPRINT (Systolic Blood Pressure Intervention Trial) but not in those with type 2 diabetes mellitus in ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure).
- The results of the current analyses show that intensive systolic blood pressure lowering decreased the risk of cardiovascular disease events and all-cause mortality similarly in SPRINT participants and ACCORD BP participants on standard glycemic control but not in ACCORD BP participants on intensive glycemic control.

What Are the Clinical Implications?

- These findings support the current American College of Cardiology and American Heart Association guidelines of a systolic blood pressure goal of <130 mm Hg in patients both with and without type 2 diabetes mellitus.

Beginning in the 1960s, randomized controlled trials demonstrated the value of treating high diastolic blood pressure and, subsequently, high systolic blood pressure (SBP). However, the treatment target for SBP has been uncertain. Several recent meta-analyses support “intensive” SBP lowering in patients with and without diabetes mellitus, but these included randomized controlled trials that targeted a higher SBP goal (<140 mm Hg or even higher) for “intensive” SBP control or blood pressure medication trials that did not have a predefined SBP goal. The recent American College of Cardiology/American Heart Association guidelines recommend an SBP goal of <130 mm Hg in patients with and without diabetes mellitus.

Whether the SBP goal should be even lower, particularly <120 mm Hg, could be debated. Two large randomized controlled trials sponsored by the National Institutes of Health (NIH) tested an SBP goal of <120 mm Hg. Both studies compared the effects of intensive (SBP target <120 mm Hg) and standard (SBP target <140 mm Hg) SBP treatment targets on cardiovascular disease (CVD) events. The first of these trials was ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) in patients with type 2 diabetes mellitus (T2DM). In addition to intensive versus standard SBP targets, in a 2×2 factorial design, ACCORD BP also tested intensive versus standard glycemic targets (glycated hemoglobin ≤6% versus 7.0–7.9%). In the primary analysis that combined the intensive and standard glycemia arms, ACCORD BP showed a nonsignificant 12% decrease in the primary composite CVD end point, along with a nonsignificant 7% increase in all-cause mortality for the SBP intervention.

In SPRINT (Systolic Blood Pressure Intervention Trial), which tested the same SBP targets in patients without diabetes mellitus, the BP intervention was stopped early because intensive SBP lowering resulted in a substantial reduction in both the primary composite CVD end point and all-cause mortality.

Reasons for these discrepant findings remain widely debated. Because ACCORD BP had fewer participants than SPRINT and the observed event rate was half the event rate assumed for power calculations in ACCORD BP, it has been suggested that ACCORD BP was underpowered. Nonetheless, despite the smaller sample size, the reported number of events and event rates in ACCORD BP were higher than in SPRINT. ACCORD BP reported an interaction P value of 0.08 for comparison of the effects of intensive SBP control on the primary composite CVD end point in the standard glycemia versus intensive glycemia arms. Another ACCORD BP report noted that compared with the combined standard SBP and standard glycemia group, intensive management of either SBP or glycemia alone improved major CVD outcomes. These findings raise the possibility that potential interactions between the intensive glycemia and SBP interventions in ACCORD BP might have masked beneficial effects of the SBP intervention.

In this study, we compared the effects of intensive SBP lowering on the composite CVD end point and all-cause mortality in SPRINT with its effects within each of the glycemia arms in ACCORD BP. We hypothesized that an interaction between the ACCORD BP glycemic and SBP interventions masked the potential beneficial effects of intensive SBP lowering in ACCORD BP. Furthermore, we investigated whether the effects of the intensive SBP intervention changed following early discontinuation of the intensive glycemia intervention in ACCORD BP.

Methods

Limited data from the SPRINT and ACCORD BP data sets are available from National Heart, Lung, and Blood Institute (NHMLBI) data repository for reproducing or replicating the results of this analysis. The Statistical Analysis section provides details of analytical procedures.

The current study was based on a secondary analysis of the limited-access SPRINT BioLINCC data set obtained from the NIH and direct analyses of the ACCORD BP database. The SPRINT and ACCORD BP studies were approved by the institutional review board at each participating study site. All participants provided written informed consent.
Table 1. Baseline Characteristics by SBP Groups in SPRINT (n=9361) and ACCORD-BP Standard (n=2362) and Intensive Glycemia (n=2371) Arms*

|                      | SPRINT Standard SBP | SPRINT Intensive SBP | ACCORD-BP Standard Glycemia | ACCORD-BP Intensive SBP | ACCORD-BP Standard SBP | ACCORD-BP Intensive SBP |
|----------------------|----------------------|----------------------|-------------------------------|-------------------------|-------------------------|-------------------------|
| n                    | 4683                 | 4678                 | 1178                          | 1184                    | 1193                    | 1178                    |
| Age, y               | 67.9±9.5             | 67.9±9.4             | 62.7±6.7                      | 62.8±6.8                | 62.8±6.8                | 62.6±6.4                |
| Female sex, %        | 35.2                 | 36.0                 | 47.1                          | 46.9                    | 48.2                    | 48.6                    |
| White race, %        | 57.7                 | 57.7                 | 59.5                          | 58.7                    | 55.9                    | 61.0                    |
| Never smoked, %      | 44.2                 | 43.8                 | 45.4                          | 45.9                    | 44.8                    | 43.4                    |
| SBP, mm Hg           | 140±15               | 140±16               | 140±15                        | 138±16                  | 139±15                  | 139±16                  |
| DBP, mm Hg           | 78±12                | 78±12                | 76±10                         | 76±10                   | 76±10                   | 76±10                   |
| Clinical atherosclerotic disease, %† | 20.0 | 20.0 | 33.3 | 33.0 | 33.4 | 35.1 |
| Antihypertensive agents (no./patient) | 1.8±1.0 | 1.8±1.0 | 1.7±1.1 | 1.7±1.2 | 1.6±1.1 | 1.7±1.1 |
| Duration of diabetes mellitus | NA | NA | 9.0 (5.0, 15.0) | 9.0 (5.0, 15.0) | 10.0 (5.0, 16.0) | 9.0 (5.0, 15.0) |
| Glycated hemoglobin% | Not reported         | Not reported         | 8.3±1.0                       | 8.3±1.0                 | 8.3±1.0                 | 8.3±1.0                 |
| Fasting plasma glucose, mg/dL | 99±13 | 99±14 | 173±55                         | 175±55                  | 172±54                  | 175±55                  |
| BMI, kg/m²           | 29.8±5.7             | 29.9±5.8             | 32.1±5.2                      | 32.3±5.6                | 32.1±5.5                | 32.1±5.6                |
| Estimated MDRD GFR, mL/min/1.73 m² | 72±21 | 72±21 | 91±23                          | 91±23                   | 91±23                   | 90±24                   |
| Urine albumin creatinine ratio, mg/g | 9.4 (5.6, 21.8) | 9.6 (5.7, 21.1) | 16.0 (7.0, 56.0) | 15.0 (7.0, 45.0) | 14.0 (7.0, 42.0) | 15.0 (7.0, 46.0) |

Percentages are reported for categorical variables and mean±SD or median (25th, 75th percentiles) for continuous variables. ACCORD BP indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; NA, not assessed; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.

*All P values of comparison between standard and intensive SBP were ≥0.05 except SBP (P=0.03) in the ACCORD BP standard glycemia arm and white race (P=0.01) in the ACCORD BP intensive glycemia arm.

†Clinical atherosclerotic disease was defined in ACCORD as one or more of myocardial infarction, stroke, angina, coronary artery bypass grafting, percutaneous coronary intervention, or other revascularization procedure. Clinical atherosclerotic disease was defined in SPRINT as ≥1 of myocardial infarction, acute coronary syndrome, coronary revascularization, carotid revascularization, peripheral artery disease with revascularization, >50% stenosis of coronary/carotid/lower extremity artery; or abdominal aortic aneurysm ≥5 mm.

Action to Control Cardiovascular Risk in Diabetes Blood Pressure

Details of the study population, interventions, and study procedures for ACCORD BP are provided in the supplement and published elsewhere.15 In brief, ACCORD was a randomized controlled trial sponsored by the NHLBI to simultaneously examine the effects of glycemic control, SBP control, and treatment with fenofibrate on a background of statin on CVD outcomes in 10 251 participants aged ≥40 years with T2DM at high risk for CVD events and a glycated hemoglobin level ≥7.5%.16 Using a double 2×2 factorial design, all 10 251 participants were randomly assigned to intensive (HbA1c [hemoglobin A1c] target <6.0%) or standard (HbA1c target 7.0–7.9%) glycemic therapy.16 In addition, 4733 of the trial participants were randomly assigned to intensive (target <120 mm Hg) or standard SBP-lowering therapy (target <140 mm Hg; ACCORD BP trial).9 Another 5518 participants were randomly assigned to receive fenofibrate or placebo on a background of simvastatin17 (ACCORD Lipid trial). The current analysis was based on participants in the ACCORD BP trial.

ACCORD BP Intervention and Follow-up

Eligible participants were randomly assigned to either intensive or standard SBP control, stratified by clinical site. Details of the ACCORD BP measurement and intervention algorithm are provided in the supplement. In brief, participants in the intensive SBP group were seen at least once a month for 4 months, with additional monthly visits if needed for titration to their SBP goal, and every 2 months thereafter; participants in the standard SBP group were scheduled at months 1 and 4 and every 4 months thereafter.

Systolic Blood Pressure Intervention Trial

SPRINT participants were recruited between November 2010 and March 2013. Adults aged ≥50 years with SBP 130 to 180 mm Hg and high CVD risk were recruited. A major exclusion criterion was presence of diabetes mellitus. Further details of SPRINT inclusion and exclusion criteria were published elsewhere and are provided in the supplement.10,11
Figure 1. Cumulative incidence of composite CVD end point (A–D) and all-cause mortality (E–H) in intensive and standard SBP groups. A, Composite CVD end point in SPRINT. B, Composite CVD end point in ACCORD BP standard glycemia arm. C, Composite CVD end point in ACCORD BP intensive glycemia arm. D, Composite CVD end point in ACCORD BP combined glycemia arms. E, All-cause mortality in SPRINT. F, All-cause mortality in ACCORD BP standard glycemia arm. G, All-cause mortality in ACCORD BP intensive glycemia arm. H, All-cause mortality in ACCORD BP combined glycemia arms. ACCORD BP indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CVD, cardiovascular disease; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.

DOI: 10.1161/JAHA.118.009326
Participants in both arms were seen monthly for the first 3 months and every 3 months thereafter. Additional monthly visits could be scheduled for drug titration to meet the assigned SBP goal. Blood pressure measurement and SBP goals were similar to those used in the ACCORD BP trial. A decision to stop the SPRINT intervention was made August 20, 2015, because of beneficial effects of the intensive SBP reduction. Only events and follow-up time that occurred on or before August 20, 2015, were included in this analysis.

**Definition of CVD Outcomes**

The primary end point in SPRINT was a composite of nonfatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from CVD causes. The primary CVD end point in ACCORD BP was similar to that of SPRINT except that it did not include acute decompensated heart failure or acute coronary syndrome. To match the SPRINT experience as closely as possible, we defined a modified composite CVD end point in ACCORD BP as a composite of the primary ACCORD BP CVD end point or congestive heart failure or unstable angina. In sensitivity analyses, we compared the SPRINT-protocol-defined primary composite CVD end point in SPRINT participants with the ACCORD BP–protocol-defined primary composite CVD end point in each of the glycemia arms in ACCORD BP.

**Statistical Analysis**

We compared patient characteristics and outcomes between the intensive SBP and standard SBP groups for the 9361 SPRINT participants, the 2362 ACCORD BP participants who were randomized to the standard glycemia arm, and the 2371 ACCORD BP participants who were randomized to the intensive glycemia arm. We summarized baseline participant characteristics by SBP group separately within each cohort. We present mean SBP with 95% confidence intervals (CIs) in

---

**Figure 2.** Effects of intensive SBP control on the composite CVD end point (A) and all-cause mortality (B) in SPRINT and ACCORD BP. ACCORD BP indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; CVD, cardiovascular disease; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.

### Composite CVD endpoint

|                  | Intensive SBP | Standard SBP |
|------------------|---------------|--------------|
| SPRINT (N=9361)  | 243(1.65)     | 319(2.19)    |
| ACCORD BP        |               |              |
| Standard glycemia arm (N=2362) | 102(2.96)     | 205(3.85)    |
| Intensive glycemia arm (N=2371) | 161(3.02)     | 183(2.91)    |
| Combined glycemia arms (N=4733) | 323(3.00)     | 368(3.36)    |

|                  | Hazard ratio (95% CI) |
|------------------|-----------------------|
| SPRINT (N=9361)  | 0.75(0.64–0.89)       |
| ACCORD BP        |                       |
| Standard glycemia arm (N=2362) | 0.77(0.63–0.95)       |
| Intensive glycemia arm (N=2371) | 1.04(0.83–1.29)       |
| Combined glycemia arms (N=4733) | 0.89(0.76–1.03)       |

**All-cause mortality**

|                  | Intensive SBP | Standard SBP |
|------------------|---------------|--------------|
| SPRINT (N=9361)  | 155(1.03)     | 210(1.39)    |
| ACCORD BP        |               |              |
| Standard glycemia arm (N=2362) | 64(1.08)     | 77(1.29)     |
| Intensive glycemia arm (N=2371) | 86(1.48)     | 67(1.10)     |
| Combined glycemia arms (N=4733) | 150(1.28)    | 144(1.19)    |

|                  | Hazard ratio (95% CI) |
|------------------|-----------------------|
| SPRINT (N=9361)  | 0.73(0.60–0.90)       |
| ACCORD BP        |                       |
| Standard glycemia arm (N=2362) | 0.85(0.61–1.19)       |
| Intensive glycemia arm (N=2371) | 1.34(0.98–1.85)       |
| Combined glycemia arms (N=4733) | 1.08(0.86–1.36)       |

Interaction p-values for comparisons of the effects of intensive SBP versus standard SBP:

|                                | For composite CVD endpoint | For all-cause mortality |
|--------------------------------|----------------------------|-------------------------|
| SPRINT vs. ACCORD BP standard glycemia arm | 0.87                       | 0.46                    |
| SPRINT vs. ACCORD BP intensive glycemia arm | 0.023                      | 0.002                   |
| ACCORD BP intensive vs. standard glycemia arm | 0.053                      | 0.051                   |
| SPRINT vs. ACCORD BP combined glycemia arms | 0.16                       | 0.015                   |

DOI: 10.1161/JAHA.118.009326

**SPRINT SBP Intervention and Follow-up**

Participants in both arms were seen monthly for the first 3 months and every 3 months thereafter. Additional monthly visits could be scheduled for drug titration to meet the assigned SBP goal. Blood pressure measurement and SBP goals were similar to those used in the ACCORD BP trial. A decision to stop the SPRINT intervention was made August 20, 2015, because of beneficial effects of the intensive SBP reduction. Only events and follow-up time that occurred on or before August 20, 2015, were included in this analysis.
the intensive and standard SBP groups for each cohorts at baseline and at each follow-up visit.

We used time-to-event methods to evaluate the effects of the SBP intervention on the composite CVD end points and all-cause mortality in each cohort and to provide pairwise comparison of the effects of the SBP intervention across the 3 cohorts and between SPRINT and ACCORD BP after pooling across the 2 glycemia arms. Our primary analyses censored follow-up at the last outcome event ascertainment, with event rates expressed as number of events per patient-year. We used Kaplan–Meier curves to depict the cumulative incidence of the composite CVD end points and all-cause mortality over follow-up. We applied Cox proportional hazards regression analyses to estimate hazard ratios (HRs) between the groups with intensive and standard SBP goals. We combined all 3 cohorts into a single analysis and performed Cox regression with stratification of the baseline hazard by study cohort and by clinical site in SPRINT and by clinical center network in ACCORD BP. The Cox models were parameterized to estimate separate HRs within each cohort and a pooled HR across the 2 glycemia control interventions of ACCORD BP. Comparisons among these HRs to evaluate interactions between the SBP intervention and the 3 cohorts were performed using likelihood ratio tests. These comparisons were repeated after censoring the follow-up of the ACCORD BP patients at the termination of the glycemia intervention when this occurred.

Figure 3. Cumulative incidence of the composite CVD end point and all-cause mortality in the intensive and standard SBP groups before and after intensive glycemia intervention was discontinued in the ACCORD BP intensive glycemia arm. A, Composite CVD end point before intensive glycemia intervention was discontinued. B, Composite CVD end point after intensive glycemia intervention was discontinued. C, All-cause mortality before intensive glycemia intervention was discontinued. D, All-cause mortality after intensive glycemia intervention was discontinued. Because the entire duration of the study is presented and the duration before intensive glycemia intervention was discontinued was much longer than the duration after intensive glycemia intervention was discontinued, the x- and y-axes scales are different for the before and after panels. Please see Figure S3 for graphic depiction of incidence of events during the first 14 months after randomization and the 14 months after discontinuation of the glycemia intervention. ACCORD BP indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CVD, cardiovascular disease; SBP, systolic blood pressure.
before the patient’s last outcome ascertainment. In sensitivity analyses, the Cox regressions comparing randomized SBP groups were repeated in the ACCORD BP participants using the ACCORD BP–protocol-defined primary composite CVD end point.

In addition to these analyses, which compared participants according to their randomized treatment assignment, we applied time-dependent Cox regression in the intensive glycemia arm of ACCORD BP to compare the HR for current exposure to the intensive versus standard SBP intervention before and after the early discontinuation of the glycemia intervention on February 5, 2008.

We also present Kaplan–Meier curves for the cumulative incidence of the composite CVD end point and all-cause death within the 2 SBP groups following the discontinuation of the glycemia intervention, with time 0 reset to the discontinuation date.

In addition, we performed a sensitivity analysis to compare the HR for the intensive versus standard SBP intervention in the first 14 months following initial randomization to the HR for the 14 months after discontinuation of the glycemia intervention in the intensive glycemia arm in ACCORD BP.

We performed all analyses in SAS v9.4 (SAS Institute) and R v3.4.3 (R Foundation for Statistical Computing). We used a 2-sided α=0.05 for hypothesis tests, without adjustment for multiple comparisons.

Results

The current analysis included 9361 SPRINT participants and 4733 ACCORD BP participants (Figure S1). Baseline demographic, clinical, and laboratory characteristics were similar in the intensive and standard SBP groups within SPRINT and within both ACCORD BP glycemia arms (Table 1). However, compared with the SPRINT participants, the ACCORD BP participants were younger, more often female, and had higher mean body mass index, mean estimated glomerular filtration rate, and median value of albuminuria (Table S1). Baseline blood pressure and number of antihypertensive medications were similar in both studies.

The intervention lowered SBP in SPRINT and ACCORD BP with similar average differences in SBP between the 2 SBP treatment groups in SPRINT, the ACCORD BP standard glycemia arm, and the ACCORD BP intensive glycemia arm (Figure S2).

Mean durations of follow-up in SPRINT and ACCORD BP were 3.22±0.85 and 4.95±1.19 years, respectively.

### Intensive SBP Lowering and the Risk of CVD Events and All-Cause Mortality During the Entire Follow-up in Both Studies

Cumulative incidences of the composite CVD end points (Figure 1A–1D) and all-cause mortality (Figure 1E–1H) were lower in the intensive SBP group compared with the standard SBP group in SPRINT and in the ACCORD BP standard glycemia arm but not in the ACCORD BP intensive glycemia arm. HRs for the composite CVD end point in the intensive versus standard SBP groups in SPRINT (HR: 0.75; 95% CI, 0.64–0.89) and the ACCORD BP standard glycemia arm (HR: 0.77; 95% CI, 0.63–0.95) were virtually identical, with an interaction \( P=0.87 \) (Figure 2A). In contrast, the HR for the groups with intensive versus standard SBP goals in the ACCORD BP intensive glycemia arm (HR 1.04, 95% CI 0.83–1.29) was significantly different (interaction \( P=0.023 \)) from that noted in SPRINT (Figure 2A).

All-cause mortality HRs for the SPRINT intensive versus standard SBP groups (HR: 0.73; 95% CI, 0.60–0.90) and ACCORD BP standard glycemia arm (HR: 0.85; 95% CI, 0.61–1.19) were also similar, with an interaction \( P=0.46 \) (Figure 2B). In contrast, the HR for all-cause mortality with intensive SBP lowering in the ACCORD BP intensive glycemia arm (HR: 1.34; 95% CI, 0.98–1.85) was significantly different (interaction \( P=0.002 \)) from that in SPRINT (Figure 2B).

In sensitivity analyses, when the ACCORD BP–protocol-defined primary composite CVD end point (excluding heart failure and unstable angina) was used in ACCORD BP, the HRs for the intensive versus standard SBP comparisons were similar to those presented using the SPRINT-like definition for the CVD outcome (Figure S3).

### CVD Events and All-Cause Mortality in the Combined Glycemia Arms in ACCORD BP

The cumulative incidence of CVD events (Figure 1D) and all-cause mortality (Figure 1H) in the combined glycemia arms in ACCORD BP reflected the summation of the effects of intensive SBP intervention on the cumulative incidence of
CVD events in the standard and intensive glycemia arms (Figure 1B, 1C, 1F, and 1G). Similarly, the HRs for composite CVD end point and all-cause mortality with intensive SBP lowering in the combined glycemia arms reflected the summation of the HRs for these events within each glycemia arm (Figure 2A and 2B).

Effects of Intensive SBP Lowering on the Composite CVD End Point and All-Cause Mortality Before and After Discontinuation of the Glycemia Intervention in the Intensive Glycemia Arm of ACCORD BP

Incidence of the CVD composite end point and all-cause deaths in the intensive and standard SBP groups before and after discontinuation of the glycemia intervention within the intensive glycemia arm of ACCORD BP are depicted in Figure 3. In a time-dependent Cox regression (Table 2) performed in participants randomized to the intensive glycemia arm of ACCORD BP, the HR for the effects of intensive SBP lowering was 1.15 (95% CI, 0.90–1.46) on the glycemia intervention and 0.64 (95% CI, 0.38–1.01) after the intensive glycemia intervention was discontinued (interaction P = 0.052). Similar results were obtained for all-cause mortality, with HRs of 1.67 (95% CI, 1.13–2.45) before and 0.79 (95% CI, 0.44–1.44) after discontinuation of the intensive glycemia intervention (interaction P = 0.041). In sensitivity analyses, results were similar when CVD events and all-cause deaths in the first 14 months during intensive glycemia intervention were compared with CVD events and all-cause deaths in the standard and intensive glycemia arms (Figure 1B, 1C, 1F, and 1G). Similarly, the HRs for composite CVD end point and all-cause mortality with intensive SBP lowering in the combined glycemia arms reflected the summation of the HRs for these events within each glycemia arm (Figure 2A and 2B).

Figure 4. Effects of intensive SBP control on the composite CVD end point (A) and all-cause mortality (B) in SPRINT and before the glycemia intervention was discontinued in ACCORD BP. ACCORD BP indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; CVD, cardiovascular disease; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.

DOI: 10.1161/JAHA.118.009326

Journal of the American Heart Association
deaths in the first 14 months after discontinuation of the intensive glycemia intervention (Figure S4).

Comparison of the Effects of Intensive SBP Lowering on the Risk of CVD Events and All-Cause Mortality in SPRINT and in ACCORD BP Before Discontinuation of the Intensive Glycemia Intervention

The HRs of intensive SBP lowering for the composite CVD end point or all-cause mortality in SPRINT were not different from those in the standard glycemia arm of ACCORD BP before discontinuation of the intensive glycemia intervention (Figure 4A and 4B). The HRs of intensive SBP lowering for the composite CVD end point and all-cause mortality during the glycemia intervention in the intensive glycemia arm were significantly different from SPRINT (interaction \( P=0.006 \) for the composite CVD end point and \( P<0.001 \) for all-cause mortality).

Comparison of the Effects of Intensive SBP Lowering on the Risk of Individual Components of the Primary Composite CVD End Point in SPRINT and in ACCORD BP Before Discontinuation of the Intensive Glycemia Intervention

In general, intensive SBP lowering was associated with reductions in CVD death (Figure 5), congestive heart failure (Figure 6), and myocardial infarction/coronary heart disease events (Figure 7) in SPRINT and in the ACCORD BP standard glycemia arm but was associated with increases in these events in the ACCORD BP intensive glycemia arm. In contrast, intensive SBP lowering was associated with reductions in
stroke across SPRINT and both ACCORD BP glycemia arms (Figure 8).

**Discussion**

The results of these post hoc comparisons of the effects of intensive SBP lowering on CVD events and all-cause mortality between SPRINT and ACCORD BP indicate that the effects of intensive SBP lowering were similar in SPRINT and the ACCORD BP standard glycemia arm. In contrast, the effects of intensive SBP lowering were significantly different between SPRINT and the ACCORD BP intensive glycemia arm. Furthermore, the apparent increased risk of CVD events and all-cause mortality with intensive SBP lowering during the intensive glycemia intervention appeared to dissipate after discontinuation of the glycemia intervention.

The reasons for the lack of statistical significance between the primary composite CVD end point in the ACCORD BP trial intensive versus standard SBP treatment arms remain widely debated, given the highly significant findings observed in SPRINT. A participant-level pooled meta-analysis of SPRINT and ACCORD BP participants suggested that in the combined cohort, intensive SBP lowering decreased the risk of CVD events. Differences in blood pressure measurement techniques, differences in the achieved SBP separations, and differences in selection criteria have also been proposed as potential explanations. Although these explanations are possibilities, other potential explanations merit consideration. Perhaps the most widely cited reason for the discordant results is a lack of statistical power in ACCORD BP. However, the total numbers of CVD and death events were actually higher in ACCORD BP because of a higher event...
rate and longer duration of follow-up. Consequently, a lack of statistical power in ACCORD BP compared with SPRINT does not appear to provide a sufficient explanation for the divergent results.

An alternative explanation is that there was an interaction between the intensive glycemia intervention and the intensive SBP lowering intervention in ACCORD BP that may have masked the potential beneficial effects of the SBP intervention. This hypothesis is supported by 2 aspects of the results of the current analysis. First, intensive SBP lowering appeared to reduce the risk of CVD events and all-cause mortality in the standard glycemia arm but not in the intensive glycemia arm of the ACCORD BP trial. In an analysis of the combined glycemia arms, these competing effects resulted in a non-significant decrease in CVD event risk and a non-significant increase in all-cause mortality risk. Second, as suggested by Table 2 and Figure 3, apparent deleterious effects of intensive SBP lowering in the intensive glycemia arm of ACCORD BP appeared to dissipate after discontinuation of the intensive glycemia intervention.

Biological plausibility exists for an interaction between intensive glycemic control and intensive SBP control. Compared with patients without diabetes mellitus, adults with T2DM have diminished myocardial glucose extraction and utilization despite similar levels of plasma insulin and higher plasma glucose levels. This may limit the ability of the myocardium in patients with T2DM to withstand ischemia and may contribute to the increased CVD morbidity and mortality in these patients. Therefore, in the setting of intensive glycemic control in T2DM, intensive SBP lowering compared with standard SBP control might result in worse CVD outcomes. This premise is supported by analysis of the individual components of the primary composite CVD end point; intensive SBP lowering appeared to increase cardiac

---

**Figure 7.** Effects of intensive SBP control on myocardial infarction/coronary heart disease events in SPRINT and before the glycemia intervention was discontinued in ACCORD BP. ACCORD BP indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.
events but not stroke. Consequently, the myocardium might be uniquely susceptible to intensive SBP lowering in the setting of intensive glycemic control.

A previous ACCORD BP report noted that, compared with the combined standard SBP and standard glycemia group, intensive management of either SBP or glycemia alone improved major CVD outcomes.\textsuperscript{13} We noted similar findings for CVD event rates during the entire period of follow-up. The major difference between the current and previous reports is that the current analysis used SPRINT as the external reference point and compared CVD events and all-cause mortality in the standard and intensive glycemia treatment arms separately. In addition, we examined the effects of intensive SBP lowering before and after discontinuation of the intensive glycemia intervention within the intensive glycemia arm of ACCORD BP. Because intensive glycemia treatment is no longer recommended because of its increased all-cause mortality risk,\textsuperscript{24} we believe that the benefits from intensive SBP lowering in the standard glycemia arm of ACCORD BP are clinically relevant for the management of hypertension in patients with T2DM. The current analysis supports intensive SBP lowering for CVD protection in patients with T2DM on standard glycemic control.

A limitation of the current study is that it was based on post hoc analyses. The ACCORD BP trial was analyzed using a prespecified factorial design in which the analysis of the effect of the intensive SBP intervention was based on an overall intensive versus standard SBP comparison in which the results were aggregated across both the intensive and standard glycemia control groups. This type of analysis assumes minimal or no interaction between the treatments being studied. Nonetheless, our post hoc analysis cannot fully exclude the possibility that the interactions between the SBP and glycemic control interventions in ACCORD BP were due to chance.

In conclusion, results of the current analyses support the possibility that intensive SBP lowering offers similar

Figure 8. Effects of intensive SBP control on stroke in SPRINT and before the glycemia intervention was discontinued in ACCORD BP. ACCORD BP indicates Action to Control Cardiovascular Risk in Diabetes Blood Pressure; CI, confidence interval; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.

|                  | Intensive SBP | Standard SBP |
|------------------|---------------|--------------|
| **N events (% yr)** |               |              |
| SPRINT (N=9381)  | 62 (0.41)     | 70 (0.47)    |
| ACCORD           |               |              |
| Standard glycemia arm (N=2382) | 15 (0.32) | 24 (0.51) |
| Intensive glycemia arm (N=2371) | 15 (0.33) | 20 (0.42) |
| Combined glycemia arms (N=4733) | 30 (0.33) | 44 (0.47) |

Hazard ratio of stroke before discontinuation of glycemia intervention (Intensive SBP vs. Standard SBP)

Interaction p-values for comparisons of the effects of intensive SBP versus standard SBP

- SPRINT vs. ACCORD BP standard glycemia arm 0.30
- SPRINT vs. ACCORD BP intensive glycemia arm 0.72
- ACCORD BP intensive vs. standard glycemia arm 0.67
- SPRINT vs. ACCORD BP combined glycemia arms 0.41
beneficial effects in patients without diabetes mellitus and in patients with T2DM on standard glycemic control. There appears to be an interaction between intensive SBP lowering and intensive glycemic control that resulted in increased CVD events and all-cause mortality and that dissipated after discontinuation of the intensive glycemia intervention. This interaction between intensive SBP lowering and intensive glycemic control is the likely explanation for the discordant results noted between SPRINT and the combined glycemia arms of ACCORD BP. Taken together, these randomized comparisons support intensive SBP lowering in patients without diabetes mellitus and in patients with T2DM on standard glycemic control, as suggested by recent guidelines.8

Acknowledgments

All authors are SPRINT (Systolic Blood Pressure Intervention Trial) investigators. Ambrosius, Cutler, Fine, and Cushman are also ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) investigators. This article was prepared using SPRINT data obtained from the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center. The views expressed in this article are those of the authors and do not represent the official position of the National Institutes of Health (NIH), the US Department of Veterans Affairs, the US government, or the SPRINT Research Group or the ACCORD Study Group. This article was approved by the SPRINT Publications and Presentations Committee. The SPRINT investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals International, Inc. All components of the SPRINT study protocol were designed and implemented by the SPRINT investigators. The investigative team collected, analyzed, and interpreted the data. All aspects of article writing and revision were carried out by the coauthors.

Sources of Funding

Statistical analyses and preparation of this article were supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK091437 and R21 DK106574) and the University of Utah Study Design and Biostatistics Center (funded in part from the Public Health Services research grant numbers UL1RR000439 and C06RR11234 from the National Center for Research Resources). SPRINT (Systolic Blood Pressure Intervention Trial) is funded with federal funds from the National Institutes of Health, including the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke under contract nos. HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, and interagency agreement no. A-HL-13-002-001. It was also supported in part with resources and use of facilities through the US Department of Veterans Affairs. We also acknowledge the support from the following Clinical and Translational Science Awards funded by the National Center for Advancing Translational Science: Case Western Reserve University: UL1TR000439, Ohio State University: UL1RR025755, University of Pennsylvania: UL1RR024134 & UL1TR000003, Boston University: UL1RR025771, Stanford University: UL1TR000093, Tufts University: UL1RR025752, University of Illinois: UL1TR000050, University of Pittsburgh: UL1TR000005, University of Texas Southwestern: 9U54TR000017-06, University of Utah: UL1TR000105-05, Vanderbilt University: UL1 TR000445, George Washington University: UL1TR000075, University of California, Davis: UL1 TR000002, University of Florida: UL1 TR000064, University of Michigan: UL1TR000433, Tulane University: P30GM103337 Centers of Biomedical Research Excellence Award National Institute of General Medical Sciences.

Disclosures

None.

References

1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
2. Xie X, Atkins E, Lv J, Bennett A, Neal B, Nihomiyi T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–443.
3. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–520.
4. Wright JT, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view systolic blood pressure goal for patients aged 60 years or older. Ann Intern Med. 2014;160:499–503.
5. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967.
6. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, He H, Chen J, Whelton PK, He J. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775–781.
7. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i1717.

8. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Denison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Oviabieh B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–1324.

9. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Carson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585.

10. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KG, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532–546.

11. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahaman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116.

12. Perkovic V, Rodgers A. Redefining blood-pressure targets—SPRINT starts the marathon. N Engl J Med. 2015;373:217–218.

13. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH, Lipkin EW, Narayan KVM, Riddle MC, Sood A, Goff DC. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721–1728.

14. National Heart, Lung, and Blood Institute. Biologic specimen and data repository information coordinating center. Available at: https://biolincc.nhlbi.nih.gov/home/. Accessed August 2, 2018.

15. National Heart, Lung, and Blood Institute. Action to Control Cardiovascular Risk in Diabetes (ACCORD) protocol. BioLINCC. August 13, 2013. Available at: https://biolincc.nhlbi.nih.gov/media/studies/accord/Protocol.pdf. Accessed August 2, 2018.

16. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Gough S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.

17. ACCORD Study Group, Ginsberg NH, Ehn M, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.

18. National Heart, Lung, and Blood Institute. Systolic Blood Pressure Intervention Protocol Version 4.0. BioLINCC. August 22, 2016. Available at: https://biolincc. nhlbi.nih.gov/media/studies/spirit_prot/Protocol.pdf. Accessed August 2, 2018.

19. Brouwer TF, Vehmeijer JT, Kalkman DN, Berger WR, van den Born B-JH, Peters RJ, Knops RE. Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials. Diabetes Care. 2018;41:1142–1148.

20. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension. 2016;67:808–812.

21. Huang C, Dhruba SS, Coppi AC, Warner F, Li SX, Lin H, Nasir K, Krumholz HM. Systolic blood pressure response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): a possible explanation for discordant trial results. J Am Heart Assoc. 2017;6:e007509. DOI: 10.1161/JAHA.117.007509.

22. Buckley LF, Dixon DL, Wohlford GF IV, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care. 2017;40:1733–1738.

23. Dutka DP, Pitt M, Pagano D, Mongillo M, Gathercole D, Bonser RS, Camici PG. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol. 2006;48:2225–2231.

24. American Diabetes Association: Standards of Medical Care in Diabetes-2017. Diabetes care. December 15, 2016. Available at: http://care.diabetesjourn alis.org/content/diacare/suppl/2016/12/15/40.Supplement_1.DC1/DC_ 40_S1_final.pdf. Accessed August 2, 2018.
Supplemental Material
Table S1. Comparison of baseline characteristics between SPRINT and ACCORD BP.

| Characteristic                        | SPRINT    | ACCORD BP | P value |
|---------------------------------------|-----------|-----------|---------|
| Age, (year)                           | 67.9 ± 9.4 | 62.7 ± 6.7 | <0.001 |
| Female sex, (%)                       | 35.6      | 47.7      | <0.001 |
| White race, (%)                       | 57.7      | 58.8      | 0.22    |
| Never smoked, (%)                     | 44.0      | 44.8      | 0.38    |
| Systolic blood pressure, (mmHg)       | 139.7 ± 15.6 | 139.0 ± 15.3 | 0.01    |
| Diastolic blood pressure, (mmHg)      | 78.1 ± 11.9 | 75.8 ± 10.0 | <0.001 |
| Clinical atherosclerotic disease* (%) | 20.1      | 33.7      | <0.001 |
| Antihypertensive agents, (no./patient)| 1.8 ± 1.0 | 1.7 ± 1.1 | 0.95    |
| Duration of diabetes, (year)          | NA        | 11.0 ± 7.8 |         |
| Glycated hemoglobin, (%)              | Not reported | 8.3 ± 1.0  |         |
| Fasting plasma glucose, (mg/dl)       | 98.8 ± 13.5 | 173.7 ± 54.6 | <0.001 |
| Body-mass index, (kg/m²)              | 29.9 ± 5.8 | 32.1 ± 5.5 | <0.001 |
| Estimated MDRD GFR#, (ml/min/1.73 m²) | 71.7 ± 20.6 | 90.5 ± 23.1 | <0.001 |
| Urine albumin creatinine ratio, (mg/g) | 9.5(5.6,21.4) | 15.0(7.0,47.0) | <0.001 |

Results are presented as a percent (for binary variables) or as mean ± SD (for continuous variables other than ACR) or as median with interquartile range (for ACR).

* Clinical atherosclerotic disease was defined in ACCORD as one or more of myocardial infarction, stroke, angina, CABG, PTCI, or other revascularization procedure. Clinical atherosclerotic disease was defined in SPRINT as one or more of MI, ACS, coronary revascularization, carotid revascularization, PAD with revascularization, >50% stenosis of coronary/carotid/lower extremity artery; or AAA ≥5 mm

#Estimated by 4-variable MDRD equation

SPRINT – Systolic Blood Pressure Intervention Trial, ACCORD BP – Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial, MDRD – Modification of Diet in Renal Disease, GFR – glomerular filtration rate, CABG – Coronary Artery Bypass Grafting, PTCI – Percutaneous Coronary Intervention, MI – Myocardial Infarction, ACS – Acute Coronary Syndrome, PAD – Peripheral Artery Disease, AAA – Abdominal Aortic Aneurysm
Figure S1. CONSORT flowdiagram for SPRINT and ACCORD BP participants.

SPRINT Trial
Assessed for eligibility (n=14,692)

Excluded (n=5331)
- Were <50 year or age (n=34)
- Had low SBP and 1 min after standing (n=352)
- Were taking too many medications or SBP that was out of range (n=2284)
- Were not at increased cardiovascular risk (n=718)
- Had miscellaneous reasons (n=703)
- Did not give consent (n=587)
- Did not complete screening (n=653)

Randomized (n=9361)

Standard BP intervention (n=4683)

Discontinued intervention (242)
Lost to follow-up (134)

Analyzed (n=4683)

Intensive BP intervention (n=4678)

Discontinued intervention (224)
Lost to follow-up (111)

Analyzed (n=4678)

Standard glycemia intervention (n=2362)

Discontinued intervention (72)
Lost to follow-up (29)

Analyzed (n=2362)

Intensive glycemia intervention (n=2371)

Discontinued intervention (61)
Lost to follow-up (29)

Analyzed (n=2371)

ACCORD Trial
Assessed for eligibility (n=19,716)

Excluded (n=9465)
- Did not meet eligibility criteria (n=1915)
- Did not complete screening (n=6774)
- Eligible, but ultimately not randomized (n=776)

Randomized in overarching Glycemia trial (n=10,251)

Randomized in BP trial (n=4733)

Randomized in Lipid trial (n=5518)

SBP – systolic blood pressure, CVD – cardiovascular disease, SPRINT – Systolic Blood Pressure Intervention Trial, ACCORD–Action to Control Cardiovascular Risk in Diabetes
Figure S2. Follow-up mean SBP (95% CI) by SBP groups in SPRINT and ACCORD BP standard and intensive glycemia arms.

SBP – systolic blood pressure, SPRINT – Systolic Blood Pressure Intervention Trial, ACCORD BP – Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial
Figure S3. Effects of intensive SBP control on SPRINT protocol-defined primary CVD endpoint in SPRINT and ACCORD BP protocol-defined primary CVD endpoint in ACCORD BP.

| Composite CVD endpoint | Intensive SBP N events (% per yr) | Standard SBP N events (% per yr) | Hazard ratio (95% CI) |
|------------------------|----------------------------------|----------------------------------|----------------------|
| SPRINT (N=9361)        | 243 (1.65)                       | 319 (2.19)                       | 0.75 (0.64–0.89)     |
| ACCORD BP              |                                  |                                  |                      |
| Standard glycemia arm  | 106 (1.80)                       | 137 (2.47)                       | 0.76 (0.59–0.96)     |
| Intensive glycemia arm | 102 (1.85)                       | 100 (1.73)                       | 1.06 (0.81–1.40)     |
| Combined glycemia arms | 208 (1.87)                       | 237 (2.09)                       | 0.88 (0.74–1.07)     |

Hazard ratio of SPRINT or ACCORD BP composite CVD endpoint (Intensive SBP vs. Standard SBP)

Interaction p-values for comparisons of the effects of intensive SBP versus standard SBP

- SPRINT vs. ACCORD BP standard glycemia arm: 0.94
- SPRINT vs. ACCORD BP intensive glycemia arm: 0.038
- ACCORD BP intensive vs. standard glycemia arm: 0.09
- SPRINT vs. ACCORD BP combined glycemia arms: 0.20

SBP – systolic blood pressure, CVD – cardiovascular disease, SPRINT – Systolic Blood Pressure Intervention Trial, ACCORD BP – Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial
Figure S4. Cumulative incidence of composite CVD endpoint and all-cause mortality in intensive and standard SBP groups in the first 14 months during intensive glycemia intervention and in the first 14 months after discontinuation of the intensive glycemia intervention.

A: CVD events during glycemia intervention
B: CVD events after discontinuation of the intensive glycemia intervention
C: All-cause during glycemia intervention
D: All-cause deaths after discontinuation of the intensive glycemia intervention
SBP – systolic blood pressure, CVD – cardiovascular disease